{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104953",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104953",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for glibenclamide and CYP2C9",
  "relatedDrugs" : [ {
    "objCls" : "Drug",
    "@id" : "https://www.pharmgkb.org/data/drug/PA449782",
    "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
    "id" : "PA449782",
    "name" : "glibenclamide"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA126",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA126",
    "symbol" : "CYP2C9",
    "name" : "cytochrome P450, family 2, subfamily C, polypeptide 9"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>There are currently no dosing recommendations for glibenclamide based on CYP2C9 genotype.</p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for glibenclamide based on CYP2C9 genotype [Article:<a href=\"/pmid/21412232\">21412232</a>]. They conclude that there are no recommendations at this time.</p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Genotype </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> CYP2C9 *1/*2 </td><td> None </td><td> Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (NS) Kinetic effect (NS) </td></tr><tr><td> CYP2C9 *2/*2 </td><td> None </td><td> Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (NS) Kinetic effect (NS) </td></tr><tr><td> CYP2C9 *1/*3 </td><td> None </td><td> Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia &gt; 1.5x109/l; leucopenia &gt; 3.0x109/l; thrombocytopenia  &gt; 75x109/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test. </td></tr><tr><td> CYP2C9 *2/*3 </td><td> None </td><td> Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (NS) Kinetic effect (NS) </td></tr><tr><td> CYP2C9 *3/*3 </td><td> None </td><td> Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Minor clinical effect (S): QTc prolongation (&lt;450 ms females, &lt;470 ms males); INR increase &lt; 4.5 <br/></td></tr><tr></tr></table><ul><li>*See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"moderate\" quality.</li><li>S: statistically significant difference.</li></ul>"
}